SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Bristol-Myers Squibb Co. – ‘8-K’ for 3/18/24

On:  Monday, 3/18/24, at 8:56am ET   ·   For:  3/18/24   ·   Accession #:  1140361-24-13726   ·   File #:  1-01136

Previous ‘8-K’:  ‘8-K’ on 2/22/24 for 2/14/24   ·   Next:  ‘8-K’ on 3/18/24 for 3/13/24   ·   Latest:  ‘8-K’ on / for 4/25/24

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/18/24  Bristol-Myers Squibb Co.          8-K:8,9     3/18/24   12:239K                                   Broadridge Fin’l So… Inc

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     34K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     18K 
 7: R1          Document and Entity Information                     HTML     55K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
12: XML         XBRL Instance -- ef20024275_8k_htm                   XML     25K 
 8: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.DEF  XBRL Definitions -- bmy-20240318_def                 XML     52K 
 5: EX-101.LAB  XBRL Labels -- bmy-20240318_lab                      XML     78K 
 6: EX-101.PRE  XBRL Presentations -- bmy-20240318_pre               XML     57K 
 3: EX-101.SCH  XBRL Schema -- bmy-20240318                          XSD     17K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               16±    23K 
11: ZIP         XBRL Zipped Folder -- 0001140361-24-013726-xbrl      Zip     25K

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C: 
 i false i 000001427200000142722024-03-182024-03-180000014272us-gaap:CommonStockMember2024-03-182024-03-180000014272bmy:CelgeneContingentValueRightsMember2024-03-182024-03-180000014272bmy:One750NotesDue2035Member2024-03-182024-03-180000014272bmy:One000NotesDue2025Member2024-03-182024-03-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM  i 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i March 18, 2024

 i BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)


 i Delaware
 i 001-01136
 i 22-0790350
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)

 i Route 206 & Province Line Road
 i Princeton,  i New Jersey,  i 08543
(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: ( i 609)  i 252-4621


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 i ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
 i Common Stock, $0.10 Par Value
  
 i BMY
  
 i New York Stock Exchange
 i 1.000% Notes due 2025
  
 i BMY25
  
 i New York Stock Exchange
 i 1.750% Notes due 2035
  
 i BMY35
  
 i New York Stock Exchange
 i Celgene Contingent Value Rights
  
 i CELG RT
  
 i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.
Other Events.
 
On March 18, 2024, Bristol-Myers Squibb Company (“BMS”) issued a press release announcing the completion of its previously announced acquisition (the “Acquisition”) of Karuna Therapeutics, Inc. (“Karuna”). In the Acquisition, each share of Karuna common stock issued and outstanding immediately prior to the effective time of the Acquisition (other than certain excluded shares as described in the agreement and plan of merger entered into among BMS, Karuna and Miramar Merger Sub Inc., a wholly owned subsidiary of BMS) was automatically converted into the right to receive $330.00 in cash, without interest, and subject to any required withholding taxes. A copy of the press release announcing the closing of the Acquisition is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits
 
The following exhibits are included as part of this Current Report on Form 8-K:
 
Exhibit
No.
  
Description
99.1
  
Press Release of Bristol-Myers Squibb Company, dated March 18, 2024.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit
No.
  
Description
99.1
  
Press Release of Bristol-Myers Squibb Company, dated March 18, 2024.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
   
Dated: March 18, 2024
By:
/s/ Kimberly M. Jablonski
 
Name:
Kimberly M. Jablonski
 
Title:
Corporate Secretary


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:3/18/24None on these Dates
 List all Filings 
↑Top
Filing Submission 0001140361-24-013726   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., Apr. 27, 1:58:16.2am ET